Ollin Biosciences secured $330 million in Series B funding to advance IBI324, a VEGF/Ang2 bispecific antibody demonstrating superior anatomic and visual outcomes compared to faricimab in diabetic macular edema and wet age-related macular degeneration. Phase 3 trials will begin in late 2026, representing a significant advancement in treating leading causes of vision loss in aging populations.
Key Points
- IBI324 showed faster, greater anatomic improvements versus faricimab
- $330M funds global Phase 3 development and pipeline expansion
- Phase 3 initiation planned H2 2026 across multiple regions
Longevity Analysis
Vision preservation directly affects quality of life, independence, and cognitive engagement in older adults—factors with measurable impact on healthspan and mortality risk. Diabetic macular edema and wet age-related macular degeneration represent major drivers of functional decline and social isolation in aging. A drug candidate demonstrating superior anatomic restoration and visual gain represents a meaningful opportunity to interrupt the cascade of vision loss that often triggers broader health deterioration. Success in Phase 3 would address a significant gap in treatment options for conditions where early intervention can substantially alter functional trajectory.
Original published by LT Wire.